Non-Pharmac Cancer Drug Cover in NZ Health Insurance (2026): Caps, Limits and the Fine Print

The dollar caps and fine print on non-Pharmac cancer drug cover in NZ health insurance for 2026 — how much Southern Cross and nib actually pay, and the limits to read before you rely on it.

The phrase "non-Pharmac drug cover" sells a lot of health insurance, and for good reason. Many modern cancer medicines are not funded by Pharmac, and a single unfunded course of treatment can run into tens or even hundreds of thousands of dollars. But the cover that fills that gap comes with a number attached, and that number is often much smaller than people assume. This article sets out the actual caps, where they sit in the policy, and the conditions you have to clear before the money is paid.

TL;DR: Non-Pharmac drug cover is capped, and the base caps are modest. On older Southern Cross Wellbeing plans the non-Pharmac sub-limit ran around $8,000-$10,000 a year, and nib Ultimate Health Max included up to $20,000 a year. Optional upgrades lift cover into the hundreds of thousands. Always read your own policy's number, not the brochure headline.

What is the non-Pharmac drug benefit in a health policy?

Pharmac is the government agency that decides which medicines are publicly funded in New Zealand. It works to a fixed budget — the Medicines Budget (formerly the Combined Pharmaceutical Budget) was NZ$1.69 billion for the 2024/25 year, including a June 2024 uplift.¹ In June 2024 the Government also allocated an additional $604 million over four years to fund or widen access to more medicines, including some cancer medicines.² Even so, a number of modern cancer drugs sit outside that funded list.

A "non-Pharmac drug benefit" in a health insurance policy is the part of the cover that helps pay for those unfunded medicines — provided the drug has been approved by Medsafe (New Zealand's medicines regulator) for the condition being treated. In practice this benefit is almost always limited to cancer drugs (chemotherapy and immunotherapy), not other conditions, and only to drugs Medsafe has indicated for the specific cancer diagnosed.⁵

This matters because the gap it is meant to fill is large. A single full course of unfunded cancer treatment in New Zealand commonly costs tens of thousands of dollars and can exceed $100,000, with reported ranges around $50,000-$150,000 per course.⁸ The benefit is genuinely useful. It is also genuinely capped.

How much do Southern Cross and nib cover for non-Pharmac drugs?

This is where the brochure and the reality diverge. The base cover on most plans is far lower than the cost of a serious unfunded course, which is why insurers sell optional upgrades on top.

The table below sets out the figures in force as at 1 February 2025. Plans change, and both insurers refresh wordings periodically, so treat this as a guide to structure rather than a live quote — check your own current policy document or product disclosure statement (PDS).

Source: provider PDS and plan documents, in force as at 1 February 2025.³⁴⁶⁷ Not every plan or provider in the market is shown — check each provider's PDS for current figures.

Two things stand out. First, the base non-Pharmac caps are modest relative to the $50,000-$150,000 a course can cost.⁸ Second, the gap between base cover and a full unfunded course is what the optional upgrades are designed to close. Southern Cross's head of product has noted that coverage ranges across plans and that about 94% of claims are met within the limits that apply.⁵ That is a reassuring figure, but it is a claims-average, not a guarantee about your particular drug or dose.

Are the caps per year, per condition, or lifetime?

The honest answer is "it depends on the policy", which is exactly why reading your own wording matters.

On the plans above, the caps are generally expressed per claims year (Southern Cross) or per policy year (nib).³⁶ That is better than a lifetime cap, because the limit resets each year. But it also means a long course of treatment that straddles two policy years draws on two years of cover, while a single intensive year may exhaust the annual cap on its own.

A per-year cap is not the same as "unlimited over time." If your treatment runs for, say, eighteen months at a cost well above the annual limit, the per-year structure helps, but you can still face a shortfall within any single year. The detail that decides this is whether the cap is annual, per-condition, or lifetime, and how the policy treats a course that crosses the renewal date. That is a wording question, and the answer differs between insurers and between plans from the same insurer.

What conditions and approvals apply before they pay?

The cap is only half the picture. Several conditions sit in front of the money:

• Medsafe indication. The drug must be approved by Medsafe for the specific cancer you have been diagnosed with. A drug approved for one cancer but not yet for yours may not qualify.⁵
• Cancer drugs only. On the plans above, the non-Pharmac benefit is limited to cancer chemotherapy and immunotherapy — not unfunded drugs for other conditions.⁵⁶
• Setting and timing. nib's base non-Pharmac cover applies in hospital and at home for up to six months after admission; the Non-PHARMAC Plus add-on extends the same window.⁶⁷
• Insurer approval. Optional non-Pharmac cover (such as nib's Non-PHARMAC Plus) is subject to the insurer's approval of the treatment.⁷
• The usual policy gates. Pre-existing condition rules, stand-down periods, underwriting and your disclosure at application all still apply, as they do across the rest of the policy.

None of this is hidden — it is in the policy wording and PDS. But it is the part people skip, and it is the part that decides whether a claim is paid.

How does this differ from a trauma lump sum funding the same drugs?

People sometimes ask whether trauma cover (also called critical illness cover) does the same job. It can fund the same drugs, but it works in a completely different way, and the two are not interchangeable.

Cover under either product depends on the terms, conditions, exclusions, stand-down periods and underwriting of the specific policy, and on your disclosure. This is a summary only — always read the policy wording or PDS.

In short: the health policy benefit pays the drug bill directly but is capped and drug-specific. A trauma lump sum hands you a fixed amount with no strings, which you can put toward drugs, the mortgage, or lost income — but it runs out once spent, and the sum insured may not match the actual cost of a long course. Some people hold both, for different reasons. Which combination fits depends on your situation, and that is an advice conversation, not a one-size answer. We cover the broader priority question in which cover to buy first.

What happens when you hit the cap mid-treatment?

This is the scenario the caps make real. If your eligible drug costs exceed the annual limit, the policy pays up to the cap and the balance falls to you, unless a higher optional cap is in place.

A few points worth understanding before that moment arrives:

• You are not cut off from treatment — you simply lose the insurer's contribution above the cap for that year. The shortfall becomes a private cost.
• The cap may reset at the next policy year, depending on the wording, which can soften a course that runs long. But it does not retrospectively cover the year you exceeded.
• Structural differences matter. Southern Cross administers the non-Pharmac benefit as a sub-limit inside the chemotherapy/cancer benefit. nib's Ultimate Health Max instead draws non-Pharmac claims against its broader surgical and non-surgical benefit limits (up to $600,000 surgical / $300,000 non-surgical per policy year on the base plan).⁹ That structural difference changes how quickly a cap bites and what other cover the same money is competing with.

Because this is exactly the moment people wish they had checked, it is worth knowing your real number now rather than at diagnosis.

How to read your policy's non-Pharmac drug clause

You do not need to be an adviser to find the figures that matter. When you open your policy document or PDS, look for five things:

1. The cap. Find the dollar figure for non-Pharmac (or "unfunded", "non-subsidised") drug cover, and whether it is a sub-limit inside the cancer benefit or a separate amount.

2. The basis. Is the cap per year, per condition, or lifetime — and does it reset at renewal?

3. The drug rule. Confirm it requires Medsafe approval for the diagnosed condition, and whether it is cancer-only or broader.

4. The setting and time limits. In hospital only, or at home too, and for how long after admission.

5. The optional upgrades. Whether a higher non-Pharmac tier is available, what it costs, and what it lifts the cap to.

If the wording is unclear, that is a fair reason to ask. An independent adviser can compare the non-Pharmac terms across insurers like Southern Cross and nib side by side — including the base caps, the optional tiers, and how each one is structured — and explain what they would mean for your situation. You can compare the two head to head in our Southern Cross vs nib guide, or read more on the non-Pharmac drug gap. For where health cover sits among your other personal insurance, a review puts the whole picture together.

Frequently asked questions

What does "non-Pharmac" actually mean on a health policy? It refers to medicines that Pharmac, the government drug-funding agency, does not subsidise. Pharmac funds a limited list within a fixed budget — $1.69 billion for 2024/25.¹ A non-Pharmac drug benefit helps pay for approved unfunded medicines, in practice almost always Medsafe-indicated cancer drugs, up to the policy's cap.⁵

Is the cap really only a few thousand dollars? On the base level of some plans, the non-Pharmac sub-limit was modest — around $8,000-$10,000 a year on older Southern Cross Wellbeing plans, and up to $20,000 a year on nib Ultimate Health Max.³⁶ Optional upgrades lift this to $100,000 or $300,000 a year.⁴⁷ Your actual cap depends on the plan and any add-ons you hold.

Does it cover non-Pharmac drugs for conditions other than cancer? On the plans covered here, generally no. The non-Pharmac benefit is limited to cancer chemotherapy and immunotherapy that Medsafe has approved for the diagnosed cancer.⁵⁶ Unfunded drugs for other conditions usually fall outside this benefit.

Should I rely on this benefit instead of trauma cover? They do different jobs. The health benefit pays drug costs directly but is capped and drug-specific; trauma cover pays a fixed lump sum you can spend on anything, including drugs. Some people hold both. Which combination suits you depends on your circumstances — personalised advice works through what fits.

Are these figures still current in 2026? The figures here were in force as at 1 February 2025, before a 2026 plan refresh that lifted the Southern Cross base toward $60,000/$10,000 across both Wellbeing plans. Plans and caps change, so always confirm the number in your own current policy document or PDS rather than relying on a published figure.

This article is general information only and is not personalised financial advice. It does not take into account your particular financial situation, goals or needs. Before acting, consider whether it's right for you and seek advice tailored to your circumstances.

Whether a claim is paid depends on the terms, conditions, exclusions, stand-down periods and underwriting of the specific policy, and on your disclosure. This is a summary only — always read the policy wording / product disclosure statement. Figures are correct as at 1 February 2025 and can change. We're generally paid by commission from the insurer when you take out a policy through us; this doesn't change the premium you pay, and we manage any conflicts of interest in line with our duty to prioritise your interests — full details in our Disclosure.

Craig Smith Business Services Ltd (FSP712931), trading as Smiths Financial, holds a Class 2 licence issued by the Financial Markets Authority to provide financial advice. Smiths Financial provides advice about personal risk insurance, health insurance, general insurance, KiwiSaver, and managed funds. We are members of the Financial Dispute Resolution Service (FDRS). Written by Henry Smith, Financial Adviser; reviewed by Craig Smith, Principal Adviser. Last reviewed 1 February 2025.